Cyclophosphamide, epirubicin and cisplatin (CEP) versus epirubicin plus cisplatin (EP) in stage Ic-IV ovarian cancer: A randomized phase III trial of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg

Anti-Cancer Drugs

Volumn 10, Issue 3, 1999, Pages 257-261

  Wils, J ^a   Van Geuns, H ^b   Stoot, J ^c   Bergmans, M ^a   Boschma, F ^b   Bron, H ^c   Degen, J ^d   Erdkamp, F ^c   Van Erp, J ^e   Haest, J ^c   Iding, R ^f   Lalisang, F ^e   De Pree, N ^a   De Rooy, C ^b   Snijders, M ^b   Schepers, J ^c   Vreeswijk, J ^b   Wals, J ^d   Werter, M ^f   Wetzels, L ^a   Smeets, J ^g   Schouten, L ^h   more..

^a LAURENTIUS HOSPITAL   (Netherlands)

^b Maartens Hospital   (Netherlands)

^c Zuyderland Medical Centre   (Netherlands)

^d Gregorius Hospital   (Netherlands)

^e St Jans Hospital   (Netherlands)

^f Elizabeth Hospital   (Netherlands)

^g Pharmacia and Upjohn   (Netherlands)

^h Maastricht UMC+ Comprehensive Cancer Centre   (Netherlands)

Author keywords

Epirubicin; Ovarian cancer; Randomized phase III trial

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 20244369400     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199903000-00001     Document Type: Article

References (11)

1. Ovarian Cancer Meta-analysis Project: cyclophosphamide 1plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma. J Clin Oncol 1991; 9: 1668-74
2. Ahern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995; 13; 726-32
3. Wils J, Blijham G, Naus A, et al. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin and cyclophosphamide in stage III-IV epithelial ovarian cancer. J Clin Oncol 986; 4: 1068-73
4. Stoot J, Wils J, van Geuns H, Smeets J, Schouten L. Chemotherapy consisting of cisplatin, epirubicin and cyclophosphamide in advanced ovarian carcinoma. Cancer Invest 1993; 11: 1-5
5. SAS Technical report P-229. SAS/STAT® software: changes and enhancements, release 6.07. Cary, NC: SAS Institute 1992: 433-80
6. Qazi F, McGuire WP. The treatment of epithelial ovarian cancer. Cancer J Clin 1995; 45: 88-101
7. Vermorken J, Kobierska A, Chevallier B, et al. Phase II study of high-dose epirubicin (HDE) in ovarian cancer cancer patients previously treated with cisplatin. Proc Am Soc Clin Oncol 1995; 14: 276 (abstr)
8. McGuire WP, Hoskins BJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Eng J Med 1996; 334: 1-6
9. Piccart MJ, Bertelsen K, Stuart G, et al. Is cisplatin-paclitaxel (P-T) the standard in first-line treatment of advanced ovarian cancer (Oc Ca)? The EORTC-GCCG, NOCOVA, NCI-C and Scottish intergroup experience. Proc Am Soc Clin Oncol 1997; 16: 352a (abstr)
10. Francis P, Schneider J, Hann L, et al. Phase II trial of docetaxel in patients with platinum refractory ovarian cancer. J Clin Oncol 1994; 12: 2301-8
11. Piccart MJ, Gore M, ten Bokkel Huinink W, et al. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 1995; 87: 676-81